文献速递免疫规划慢病防控与筛查卫生政策与健康促进

成人实体器官移植受者肺炎球菌疫苗接种证据综述

Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence.
PubMed 文献 · Vaccine · 2018-09-11

本叙述性综述总结成人实体器官移植受者肺炎球菌疫苗接种的现有文献。多糖疫苗在小型队列研究中可诱导血清学应答但低于健康对照,模型估计其效力较HIV患者低三分之一;结合疫苗随机对照试验显示可产生血清学应答但序贯加强无额外获益。尚无随机研究评估临床保护率,现有国际推荐基于专家意见。

要点

  • 实体器官移植受者接种肺炎球菌疫苗可产生可测量的血清学应答,但低于健康对照。
  • 数学模型估计多糖疫苗在移植受者中的效力较HIV患者低三分之一。
  • 结合疫苗随机对照试验显示序贯加强(结合疫苗后多糖疫苗)无额外获益。

核心结论

  • 肺炎球菌疫苗接种是降低实体器官移植受者侵袭性肺炎球菌病的潜在重要策略,且安全性良好。
  • 当前国际推荐基于相互矛盾数据的专家意见,亟需高质量研究确定最佳接种方案。

研究设计与样本

  • 叙述性综述,总结成人实体器官移植受者肺炎球菌疫苗接种的现有文献。
  • 多糖疫苗证据来自多个小型队列研究,多数为肾移植受者。
  • 结合疫苗证据来自少数在肝移植和肾移植受者中开展的随机对照试验。

主要发现

  • 多数小型队列研究中移植受者能对多糖疫苗产生可测量的血清学应答,但应答低于健康对照。
  • 数学模型估计多糖疫苗在移植受者中的效力较HIV患者低三分之一。
  • 结合疫苗随机对照试验显示移植受者接种后产生血清学应答,但序贯加强(结合疫苗后多糖疫苗)无额外获益。
  • 尚无随机研究评估任一种疫苗接种后侵袭性肺炎球菌病的临床保护率,或保护率与疫苗滴度或其他抗肺炎球菌应答的关联。
  • 研究未支持接种增加排斥反应或供者特异性抗体等不良同种免疫应答风险的担忧。

临床怎么用

  • 肺炎球菌疫苗接种是降低实体器官移植受者侵袭性肺炎球菌病的潜在重要策略。
  • 当前国际推荐基于相互矛盾数据的专家意见,需个体化评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This narrative review summarizes the current literature relating to pneumococcal vaccination in adult solid organ transplant (SOT) recipients, who are at risk of invasive pneumococcal disease (IPD) with its attendant high morbidity and mortality. The effect of the pneumococcal polysaccharide vaccine has been examined in several small cohort studies in SOT recipients, most of which were kidney transplant recipients. The outcomes for these studies have been laboratory seroresponses or functional antibody titers. Overall, in most of these studies the transplant recipients were capable of generating measurable serological responses to pneumococcal vaccination but these responses were less than those of healthy controls. A mathematical model estimated the effectiveness of polysaccharide vaccination in SOT recipients to be one third less than those of patients with HIV. The evidence for the efficacy of the pneumococcal conjugate vaccine in SOT is based on a small number of randomized controlled trials in liver and kidney transplant recipients. These trials demonstrated that SOT recipients mounted a serological response following vaccination however there was no benefit to the use of prime boosting (conjugate vaccine followed by polysaccharide vaccine). Currently there are no randomized studies investigating the clinical protection rate against IPD after pneumococcal vaccination by either vaccine type or linked to vaccine titers or other responses against pneumococcus. Concerns that vaccination may increase the risk of adverse alloresponses such as rejection and generation of donor specific antibodies are not supported by studies examining this aspect of vaccine safety. Pneumococcal vaccination is a potentially important strategy to reduce IPD in SOT recipients and is associated with excellent safety. Current international recommendations are based on expert opinion from conflicting data, hence there is a clear need for further high-quality studies in this high-risk population examining optimal vaccination regimens. Such studies should focus on strategies to optimize functional immune responses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dendle C, Stuart RL, Mulley WR, et al. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence. Vaccine. 2018. PMID: 30217523. doi:10.1016/j.vaccine.2018.08.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。